News Janssen and Bavarian Nordic sign $836m deal on Hep B and HIV... Janssen has signed a new deal with Bavarian Nordic worth up to $836 million to develop target vaccines for hepatitis B and HIV.
News Gilead ordered to pay Merck & Co $2.54 bn by US court Ruling relates to infringement of patents held by Merck subsidiary
News European safety experts review latest hepatitis C drugs European safety experts are reviewing the latest generation of hepatitis C drugs following cases of re-activation of hepatitis B in patients treated with the medicines, who had been infecte
Articles Raising the bar: can Gilead’s next challenge be even bigger ... How do you follow a genuine drug breakthrough, a cure for hepatitis C?
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.